Method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof

Abstract

A new method can be used for treating colorectal cancer (CRC) and metastases thereof in subjects, and preferably also other solid cancers and metastases thereof in subjects. The method preferably depends on whether the patient shows certain specific proteins levels in one or more body fluids prior to or during treatment. The treatment involves the administration of at least one pan αv integrin inhibitor to a patient. A corresponding medicament is used in the new methods. A method can be used for predicting the outcome of a treatment with at least one pan αv integrin inhibitor based on the specific protein levels in one or more body fluids of the patient.

1 - 19 . (canceled) 
     
     
         20 : A method to identify tumours in a subject likely to benefit from treatment with at least one pan αv integrin inhibitor, said method comprising:
 determining levels of one or more proteins, selected from the group consisting of TPO (UniProt ID: P07202), CCL23.1 (UniProt ID: P55773), IGHD_IGK._IGL. (UniProt ID: P01880), STX1A (UniProt ID: Q16623), TK1 (UniProt ID: P04183), IL17A (UniProt ID: Q16552), PGF (UniProt ID: P49763), and TGM3 (UniProt ID: Q08188) in at least one body fluid of said subject, wherein: 
 a) a high level one or more proteins selected from the group consisting of: 
 TPO (UniProt ID: P07202), 
 CCL23.1 (UniProt ID: P55773), 
 IGHD_IGK._IGL. (UniProt ID: P01880), 
 TK1 (UniProt ID: P04183), 
 IL17A (UniProt ID: Q16552), 
 STX1A (UniProt ID: Q16623), and 
 PGF (UniProt ID: P49763), 
 and/or 
 b) a low level of the protein TGM3 (UniProt ID: Q08188); 
 identify a tumour likely to benefit from the treatment with at least one pan αv integrin inhibitor. 
 
     
     
         21 : A method to identify tumours in a subject likely to benefit from treatment with at least one pan αv integrin inhibitor, said method comprising:
 determining level of the protein STX1A (UniProt ID: Q16623) and/or a protein having at least 80% sequence homology to STX1A, in one or more body fluids of said subject, wherein a high level thereof identify a tumour likely to benefit from the treatment with at least one pan αv integrin inhibitor. 
 
     
     
         22 : The method according to  claim 20 , wherein the level of protein in said one or more body fluids is:
 a) classified as high, if a respective protein level in said one or more body fluid is at least 2% higher than a median threshold determined for the respective protein,   and/or   b) classified as low, if the respective protein level in said one or more body fluids is at least 2% lower than said median threshold for the respective protein.   
     
     
         23 : The method according to  claim 20 , wherein the one or more body fluids comprise a blood plasma or consist of blood plasma. 
     
     
         24 : The method according to  claim 20 , wherein the at least one pan αv integrin inhibitor comprises Abituzumab or is Abituzumab. 
     
     
         25 : A method to identify a subject responsive to treatment with at least one pan αv integrin inhibitor, the method comprising:
 determining levels of one or more proteins, selected from the group consisting of TPO (UniProt ID: P07202), CCL23.1 (UniProt ID: P55773), IGHD_IGK._IGL. (UniProt ID: P01880), STX1A (UniProt ID: Q16623), TK1 (UniProt ID: P04183), IL17A (UniProt ID: Q16552), PGF (UniProt ID: P49763), and TGM3 (UniProt ID: Q08188) in at least one body fluid of said subject, wherein 
 a) a high level one or more proteins selected from the group consisting of: 
 TPO (UniProt ID: P07202), 
 CCL23.1 (UniProt ID: P55773), 
 IGHD_IGK._IGL. (UniProt ID: P01880), 
 TK1 (UniProt ID: P04183), 
 IL17A (UniProt ID: Q16552), 
 STX1A (UniProt ID: Q16623), and 
 PGF (UniProt ID: P49763), 
 and/or 
 b) a low level of the protein TGM3 (UniProt ID: Q08188); 
 identify a subject responsive to treatment with at least one pan αv integrin inhibitor. 
 
     
     
         26 .- 28 . (canceled) 
     
     
         29 : The method according to  claim 21 , wherein the protein having at least 80% sequence homology to STX1A has at least 99% sequence homology to STX1A. 
     
     
         30 : The method according to  claim 22 , wherein the level of protein in said one or more body fluids is classified as high if the respective protein level in said one or more body fluids is at least 25% higher than said median threshold determined for the respective protein. 
     
     
         31 : The method according to  claim 22 , wherein the level of protein in said one or more body fluids is classified as low if the respective protein level in said one or more body fluids is at least 25% lower than said median threshold for the respective protein.